Company intelligence / Profile preview

Lamin

Munich, Germany

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Lamin is a Y Combinator-backed (S22) software company that develops LaminDB, an open-source data platform specifically for biology. This platform focuses on data lineage, lakehouse architecture, FAIR principles, and offers LIMS/ELN functionalities. It primarily serves computational biology R&D across pharmaceutical companies, biotech firms, and academic institutions, and is not involved in traditional drug discovery or development.

Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

PfizerEnsocell Therapeutics

Beyond the preview

Go deeper on Lamin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lamin.

Explore the full profile